Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04208971 · ClinicalTrials.gov registry record
Batch Enrollment for AI-Guided Intervention to Lower Neurologic Events in Unrecognized AF
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 1,225
- Enrollment target
NCT04208971: Completed study, sponsored by Mayo Clinic.
NCT04208971 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 1,225 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04208971 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 1,225 participants
- Enrollment target
Study Summary
This is a prospective study to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of unrecognized atrial fibrillation (AF) and stroke prevention.
Primary Outcome
The data will be used to examine the performance of the algorithm in detecting unrecognized atrial fibrillation (e.g. positive predictive value, negative predictive value, sensitivity, specificity, and area under the curve \[AUC\]).
Interventions
- OTHER AI-enabled ECG-based Screening Tool for AF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,225 participants |
| Start Date | 2020-11-02 |
| Est. Completion | 2022-01-27 |
What the finished NCT04208971 record still lists
NCT04208971 is an observational study that tracks outcomes without assigning an intervention. Its 1,225 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which AI-enabled ECG-based Screening Tool for AF is the first listed.
NCT04208971 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04208971 about?
NCT04208971 is a clinical study titled "Batch Enrollment for AI-Guided Intervention to Lower Neurologic Events in Unrecognized AF". This is a prospective study to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis of unrecognized atrial fibrillation (AF) and stroke prevention.
What is the current status of trial NCT04208971?
This trial is currently completed. The enrollment target is 1,225 participants. The study started on 2020-11-02. Estimated completion is 2022-01-27.
What interventions are being tested in trial NCT04208971?
The interventions under investigation include: AI-enabled ECG-based Screening Tool for AF (OTHER).
Who is sponsoring clinical trial NCT04208971?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
- NCT06787937 · 1,230 participants · NA
Communicating About Nicotine Reduction in Cigarettes
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI